ASP8374 + Cemiplimab in Recurrent Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04826393

Recruitment Status : Active, not recruiting

First Posted : April 1, 2021

Last Update Posted : August 3, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Regeneron Pharmaceuticals

Astellas Pharma Inc

Information provided by (Responsible Party):

David Reardon, MD, Dana-Farber Cancer Institute

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	October 31, 2022
Estimated Study Completion Date :	December 30, 2024

To Top